Leukemia Research
Volume 33, Issue 11 , Pages 1490-1498 , November 2009

Epigenetics of multiple myeloma after treatment with cytostatics and gamma radiation

  • Jana Krejčí

      Affiliations

    • Institute of Biophysics, Academy of Sciences of the Czech Republic, Královopolská 135, 612 65 Brno, Czech Republic
    • ,
  • Andrea Harničarová

      Affiliations

    • Institute of Biophysics, Academy of Sciences of the Czech Republic, Královopolská 135, 612 65 Brno, Czech Republic
    • ,
  • Denisa Štreitová

      Affiliations

    • Institute of Biophysics, Academy of Sciences of the Czech Republic, Královopolská 135, 612 65 Brno, Czech Republic
    • ,
  • Roman Hájek

      Affiliations

    • Department of Internal Medicine-Hematooncology, Masaryk University Hospital, Jihlavská 20, 625 00 Brno, Czech Republic
    • ,
  • Luděk Pour

      Affiliations

    • Department of Internal Medicine-Hematooncology, Masaryk University Hospital, Jihlavská 20, 625 00 Brno, Czech Republic
    • ,
  • Stanislav Kozubek

      Affiliations

    • Institute of Biophysics, Academy of Sciences of the Czech Republic, Královopolská 135, 612 65 Brno, Czech Republic
    • ,
  • Eva Bártová

      Affiliations

    • Institute of Biophysics, Academy of Sciences of the Czech Republic, Královopolská 135, 612 65 Brno, Czech Republic
    • Corresponding Author InformationCorresponding author. Tel.: +420 5 41517141; fax: +420 5 41211293.

Received 11 December 2008 ,Revised 9 March 2009 ,Accepted 13 March 2009.

References 

  1. Pratt G. Molecular aspects of multiple myeloma. Mol Pathol. 2002;55:273–283
  2. Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002;100:1417–1424
  3. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98:2229–2238
  4. Cremer FW, Bila J, Buck I, et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer. 2005;44:194–203
  5. Shaughnessy J, Tian E, Sawyer J, et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood. 2000;96:1505–1511
  6. Cremer FW, Kartal M, Hose D, et al. High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH. Cancer Genet Cytogenet. 2005;161:116–124
  7. Avet-Loiseau H, Gerson F, Magrangeas F, et al. Intergroupe Francophone du Myelome. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood. 2001;98:3082–3086
  8. Liu P, Leong T, Quam L, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood. 1996;88:2699–2706
  9. Harousseau JL, Shaughnessy J, Richardson P. Multiple myeloma. Hematol Am Soc Hematol Educ Program. 2004;237–256
  10. Armellini A, Sarasquete ME, García-Sanz R, et al. Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma. Br J Haematol. 2008;141:212–215
  11. Nguyen CT, Gonzales FA, Jones PA. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res. 2001;29:4598–4606
  12. Zhu WG, Hileman T, Ke Y, et al. 5-aza-2′-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem. 2004;279:15161–15166
  13. Kouzarides T. Chromatin modifications and their function. Cell. 2007;128:693–705
  14. Hodge DR, Peng B, Cherry JC, et al. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res. 2005;65:4673–4682
  15. Nielsen SJ, Schneider R, Bauer UM, et al. Rb targets histone H3 methylation and HP1 to promoters. Nature. 2001;412:561–565
  16. Bannister AJ, Kouzarides T. Reversing histone methylation. Nature. 2005;436:1103–1106
  17. McLaughlin F, La Thangue NB. Histone deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol. 2004;68:1139–1144
  18. Fišerová A, Hájek R, Holubová V, et al. Detection of 13q abnormalities in multiple myeloma using immunomagnetically selected plasma cells. Neoplasma. 2002;49:300–306
  19. Matsuo Y, Drexler HG, Harashima A, et al. Induction of CD28 on the new myeloma cell line MOLP-8 with t(11;14)(q13;q32) expressing delta/lambda type immunoglobulin. Leuk Res. 2004;28:869–877
  20. Drewinko B, Mars W, Minowada J, Burk KH, Trujillo JM. ARH-77, an established human IgG-producing myeloma cell line. I. Morphology, B-cell phenotypic marker profile, and expression of Epstein-Barr virus. Cancer. 1984;54:1883–1892
  21. Drewinko B, Mars W, Stragand JJ, et al. ARH-77, an established human IgG-producing myeloma cell line. II. Growth kinetics, clonogenic capacity, chalone production, xenogeneic transplantations, and response to melphalan. Cancer. 1984;54:1893–1903
  22. Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006;108:1724–1732
  23. Sonneveld P. Gain of 1q21 in multiple myeloma from bad to worse. Blood. 2006;108:1426–1427
  24. Turner JG, Gump JL, Zhang C, et al. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood. 2006;108:3881–3889
  25. Heller G, Schmidt WM, Ziegler B, et al. Genome-wide transcriptional response to 5-aza-2′-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res. 2008;68:44–54
  26. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol. 2001;13:477–483
  27. Krieger S, Grunau C, Sabbah M, Sola B. Cyclin D1 gene activation in human myeloma cells is independent of DNA hypomethylation or histone hyperacetylation. Exp Hematol. 2005;33:652–659
  28. Pruneri G, Fabris S, Baldini L, et al. Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Am J Pathol. 2000;156:1505–1513
  29. Wachters FM, Wong LS, Timens W, et al. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer. 2005;50:211–219
  30. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther. 1987;34:155–166
  31. Olinski R, Wedrychowski A, Schmidt WN, et al. In vivo DNA-protein cross-linking by cis- and trans-diamminedichloroplatinum(II). Cancer Res. 1987;47:201–205
  32. Zwelling LA, Anderson T, Kohn KW. DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res. 1979;39:365–369
  33. Bártová E, Kozubek S, Gajová H, Kozubek S . Cytogenetics and cytology of retinoblastomas. J Cancer Res Clin Oncol. 2003;129:89–99
  34. San-Miguel J, García-Sanz R, López-Peréz R. Analysis of methylation pattern in multiple myeloma. Acta Haematol. 2005;114:23–26
  35. Wu J, Smith LT, Plass C, Huang TH. ChIP-chip comes of age for genome-wide functional analysis. Cancer Res. 2006;66:6899–6902

PII: S0145-2126(09)00139-8

doi: 10.1016/j.leukres.2009.03.016

Leukemia Research
Volume 33, Issue 11 , Pages 1490-1498 , November 2009

Article Tools

* Image Usage & Resolution